FIRDAPSE now available in Japan for muscle weakness
CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...
Business Insider6d
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
FIRDAPSE (amifampridine) is the only U.S. FDA approved, evidence-based therapy for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder ...
Hosted on MSN17d
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...
Benzinga.com18d
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
In May, the FDA approved its supplemental New Drug Application, increasing the indicated maximum daily dose of Firdapse’s (amifampridine) for adults and pediatric patients weighing more than 45 ...